6 burning questions about how the FDA will handle conflicting abortion pill decisions
A dueling pair of federal court decisions has thrown the fate of the abortion pill mifepristone into jeopardy — and have left regulators and drugmakers navigating uncharted territory.
The Food and Drug Administration approved the drug more than two decades ago. But that approval — and the agency’s broader authority — was cast into doubt with a decision on Friday by Texas judge Matthew Kacsmaryk which ruled that regulators had erred in letting the medicine onto the market. That long-awaited decision was swiftly followed by a Washington federal court ruling ordering the agency to ensure access to the pill going forward.
